Alterations of growth, biofilm-forming, and gene expression of Bordetella pertussis by antibiotics at sub-minimum inhibitory concentrations

被引:4
作者
Delik, Eda [1 ]
Eroglu, Berfin [1 ]
colak, Cigdem Yilmaz [2 ]
Ozcelik, Aysun Turkanoglu [3 ]
Ozturk, Burcu Emine Tefon [1 ]
机构
[1] Akdeniz Univ, Fac Sci, Biol Dept, TR-07058 Antalya, Turkiye
[2] TUBITAK, Genet Engn & Biotechnol Inst, TR-41470 Kocaeli, Turkiye
[3] Akdeniz Univ, Fac Agr, Agr Biotechnol Dept, TR-07058 Antalya, Turkiye
关键词
Antimicrobials; Biofilm; Growth curve; Sub-mic; Virulence genes; Whooping cough; ANTIMICROBIAL SUSCEPTIBILITY; BPS POLYSACCHARIDE; VIRULENCE; COLONIZATION; MODULATION;
D O I
10.1016/j.resmic.2023.104058
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Bordetella pertussis is the primary agent of the acute respiratory disease pertussis. It has been reported that the disease has recently become more common, especially in adults and adolescents, and adaptation of the pathogen is thought to have an important influence on the recurrence of the disease. This study aims to determine the effect of erythromycin, azithromycin, and trimethoprim-sulfamethoxazole used in the treatment of pertussis on the virulence gene expressions (prn, ptxS1, fhaB), biofilm-forming and growth of B. pertussis. In this study, the minimum inhibitory concentration (MIC) values of azithromycin and erythromycin in B. pertussis local strain Saadet were determined to be 0.09 mg/mL and 0.3 mg/mL, respectively. However, the Tohama-I and Saadet strains were resistant to trimethoprim-sulfamethoxazole (MIC>32 mg/mL). The biofilm-forming of the Saadet strain decreased with the in-crease in antibiotic doses. It was observed that 1/32MIC erythromycin and 1/32MIC azithromycin upregulated the expression of fhaB in Tohama-I, whereas the expression of ptxS1 and prn significantly decreased in sub-MICs of erythromycin. In the Saadet strain, only ptxS1 was highly expressed at 1/16MIC azithromycin and erythromycin (p > 0.05). This is the first study to investigate the effect of sub-MIC antibiotics on the expression of virulence genes and biofilm-forming of B. pertussis.& COPY; 2023 Institut Pasteur. Published by Elsevier Masson SAS. All rights reserved.
引用
收藏
页数:7
相关论文
共 46 条
[1]  
[Anonymous], Recommended antimicrobial dosage schedules for neonates
[2]   Efficacy of short-term treatment of pertussis with clarithromycin and azithromycin [J].
Aoyama, T ;
Sunakawa, K ;
Iwata, S ;
Takeuchi, Y ;
Fujii, R .
JOURNAL OF PEDIATRICS, 1996, 129 (05) :761-764
[3]   The Role of Subinhibitory Concentrations of Daptomycin and Tigecycline in Modulating Virulence in Staphylococcus aureus [J].
Atshan, Salman Sahab ;
Hamat, Rukman Awang ;
Coolen, Marco J. L. ;
Dykes, Gary ;
Sekawi, Zamberi ;
Mullins, Benjamin J. ;
Than, Leslie Thian Lung ;
Abduljaleel, Salwa A. ;
Kicic, Anthony .
ANTIBIOTICS-BASEL, 2021, 10 (01) :1-16
[4]   Inhibition of Pseudomonas aeruginosa quorum sensing by subinhibitory concentrations of curcumin with gentamicin and azithromycin [J].
Bahari, Shahin ;
Zeighami, Habib ;
Mirshahabi, Hesam ;
Roudashti, Shekoufeh ;
Haghi, Fakhri .
JOURNAL OF GLOBAL ANTIMICROBIAL RESISTANCE, 2017, 10 :21-28
[5]   AZITHROMYCIN - THE 1ST AZALIDE ANTIBIOTIC [J].
BALLOW, CH ;
AMSDEN, GW .
ANNALS OF PHARMACOTHERAPY, 1992, 26 (10) :1253-1261
[6]   The RNA Chaperone Hfq Is Required for Virulence of Bordetella pertussis [J].
Bibova, Ilona ;
Skopova, Karolina ;
Masin, Jiri ;
Cerny, Ondrej ;
Hot, David ;
Sebo, Peter ;
Vecerek, Branislav .
INFECTION AND IMMUNITY, 2013, 81 (11) :4081-4090
[7]   Bordetella pertussis: new concepts in pathogenesis and treatment [J].
Carbonetti, Nicholas H. .
CURRENT OPINION IN INFECTIOUS DISEASES, 2016, 29 (03) :287-294
[8]   Hyperbiofilm Formation by Bordetella pertussis Strains Correlates with Enhanced Virulence Traits [J].
Cattelan, Natalia ;
Jennings-Gee, Jamie ;
Dubey, Purnima ;
Yantorno, Osvaldo M. ;
Deora, Rajendar .
INFECTION AND IMMUNITY, 2017, 85 (12)
[9]   Pharmacotherapy for Bordetella pertussis infection. II. A synthesis of clinical sciences [J].
Cimolai, Nevio .
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2021, 57 (03)
[10]  
( CLSI) calsi, 2021, PERFORMANCE STANDARD